Xeris 生物製藥控股公司
DE ˙ DB ˙ US98422E1038
€5.20 ↑0.22 (4.40%)
2026-06-05
分享價格
SecurityDE:2B30 / Xeris Biopharma Holdings, Inc.
InstitutionCwm, Llc
Latest Disclosed Ownership64,180 shares
Latest Disclosed Value $ 372,244
Cwm, Llc reports 15.94% increase in ownership of 2B30 / Xeris Biopharma Holdings, Inc.

On May 14, 2026 - Cwm, Llc filed a 13F-HR form disclosing ownership of 64,180 shares of Xeris Biopharma Holdings, Inc. (DE:2B30) valued at $309,476 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 26, 2026 disclosing 55,356 shares of Xeris Biopharma Holdings, Inc.. The current value of the position is $333,736 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 64,180 8,824 15.94 372 0.0010
2026-01-26 2025-12-31 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 55,356 -83 -0.15 0 0.0012
2025-10-15 2025-09-30 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 55,439 328 0.60 0 0.0014
2025-07-25 2025-06-30 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 55,111 -11,861 -17.71 0 0.0009
2025-05-01 2025-03-31 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 66,972 29,614 79.27 0 0.0015
2025-02-04 2024-12-31 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 37,358 3,191 9.34 0 0.0005
2024-10-08 2024-09-30 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 34,167 16,530 93.72 0 0.0004
2024-07-10 2024-06-30 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 17,637 4,454 33.79 0 0.0002
2024-04-05 2024-03-31 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 13,183 13,164 69,284.21 0 0.0001
2024-02-01 2023-12-31 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 19 19 0 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.